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Abstract
Purpose: The purpose of the present study was to evaluate the retinal toxicity of a single dose of intravitreal
docosahexaenoic acid (DHA) in rabbit eyes over a short-term period.
Methods: Sixteen New Zealand albino rabbits were selected for this pre-clinical study. Six concentrations of DHA (Brudy
Laboratories, Barcelona, Spain) were prepared: 10 mg/50 ml, 5 mg/50 ml, 2’5 mg/50 ml, 50 mg/50 ml, 25 mg/50 ml, and 5 mg/
50 ml. Each concentration was injected intravitreally in the right eye of two rabbits. As a control, the vehicle solution was
injected in one eye of four animals. Retinal safety was studied by slit-lamp examination, and electroretinography. All the
rabbits were euthanized one week after the intravitreal injection of DHA and the eyeballs were processed to morphologic
and morphometric histological examination by light microscopy. At the same time aqueous and vitreous humor samples
were taken to quantify the concentration of omega-3 acids by gas chromatography. Statistical analysis was performed by
SPSS 21.0.
Results: Slit-lamp examination revealed an important inflammatory reaction on the anterior chamber of the rabbits injected
with the higher concentrations of DHA (10 mg/50 ml, 5 mg/50 ml, 2’5 mg/50 m) Lower concentrations showed no
inflammation. Electroretinography and histological studies showed no significant difference between control and DHA-
injected groups except for the group injected with 50 mg/50 ml.
Conclusions: Our results indicate that administration of intravitreal DHA is safe in the albino rabbit model up to the
maximum tolerated dose of 25 mg/50 ml. Further studies should be performed in order to evaluate the effect of intravitreal
injection of DHA as a treatment, alone or in combination, of different retinal diseases.
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Introduction
Polyunsaturated fatty acids (PUFAs) are essential molecules
required from de diet, which are classified by the position of the
first double bound counting from the metil-terminal in omega-3 -
third carbon- (eicosapentaenoic acid, docosahexaenoic acid and a-
linolenic acid) and omega-6 -sixth carbon- (linoleic acid and
arachidonic acid). The most important omega-3 fatty acid in the
nervous system and the retina is docosahexaenoic acid (DHA),
particularly highly concentrated in the outer segments of
photoreceptors and synaptic membranes. DHA plays a key role
in cellular integrity, development and function [1] and it is an
essential structural component of cellular membranes. It also
shows a functional role, as the proper rhodopsin functionality and
visual transduction depend on the adequate proportion of DHA
within the retinal cell membranes phospholipids. [2] In addition,
DHA displays antiinflammatory properties in contrast to the
proinflammatory actions of several members of the omega-6
PUFAs family. [1]
The currently available scientific evidence suggests that DHA
may have a protective role against ischemia, oxidative stress and
aging in the retina. [3] These effects can result from independent
mechanisms such as: membrane functional integrity amelioration,
recruitment and up-regulation of anti-apoptotic molecules (as the
members of the Bcl-2 gene family) or down-regulation of pro-
apoptotic signals, regression or suppression of inflammatory
mediators. [4] All this information lead to the design of high-
dose DHA oral supplementation trials intending to prevent and to
improve the prognosis of retinal degenerative diseases.
The aim of the present study was to evaluate the preclinical
safety of intravitreal injection of purified DHA in an albino rabbit
model by evaluating functional and anatomical parameters.
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Methods
The study design and experimental protocols were approved by
the Ethics and Clinical Research Committee of the Faculty of
Medicine of the University of Valencia, (2012) in accordance with
the guidelines set forth by the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research and the European
Community guidelines regarding animal experimentation.
Animals
Sixteen adult male New Zealand albino rabbits weighing 2.6 to
3.1 kg were used for the present study. The animals were kept in
the University of Valencia in a 12-hour light-dark cycle ambient.
Slit-lamp and indirect funduscopic examinations were performed
in all animal eyes at baseline. Animals that showed corneal or lens
opacity or retinal damage were excluded.
Intravitreal injection
The drug used for the assays was DHA (purity of 70% as
triglycerides as measured by high-performance liquid chromatog-
raphy and thin-layer chromatography) obtained from Brudy
Laboratories (Barcelona, Spain). The fatty acid profiles of
nanoemulsions used in the present study are expressed in
Table 1. DHA was administered as nanoemulsions diluted with
balanced saline solution to obtain six different concentrations:
10 mg/50 ml, 5 mg/50 ml, 2.5 mg/50 ml, 50 mg/50 ml, 25 mg/
50 ml, 5 mg/5 ml. Each concentration was injected intravitreally in
the right eye of two animals.
We performed the study in two periods. Firstly we used high
doses of intravitreal DHA in order to define the maximal tolerated
Table 1. Fatty acid profiles of nanoemulsions used.
Fatty acids Mol%
Total SFA 2,360,4
Total MUFA 3,260,3
Total PUFA 94,462,0
Total Omega-6 4,961,8
Total Omega-3 89,661,5
C22:6n-3 (DHA) 88,361,8
n-6/n-3 Ratio 0,0560,1
Abbreviations: Total SFA, Total saturated fatty acids; Total MUFA, Total
monunsaturated fatty acids; Total PUFA, Total polyunsaturated fatty acids; DHA,
docosahexaenoic acid. Data are given as mean 6 SD of mol% of fatty acid.
doi:10.1371/journal.pone.0096872.t001
Figure 1. Color photographs of the eyes one week after intravitreal injection of 0.05 ml of different concentrations of DHA. Eyes
injected with 5 mg (A), 25 mg (B), and 50 mg (C) of DHA showed no inflammatory signs in the anterior segment. Eyes injected with the higher
concentrations of DHA showed ocular inflammatory signs directly proportional to the injected concentration. The eyes injected with 2.5 mg (D) and
5 mg (E) of DHA showed mild to moderate inflammation in the anterior chamber, while the eyes injected with 10 mg (F) of DHA demonstrated a
severe ocular inflammation. In one case (F, top row) a corneal ectasia appeared associated with surrounding corneal edema.
doi:10.1371/journal.pone.0096872.g001
Table 2. Comparison of baseline and 1 week post-injection ERG parameters (mV).
2 3 4
mean ± SD P value mean ± SD P value mean ± SD P value
PRE-POST Scotopic A-wave 2189,6066,56/2193,4665,07 0,416 2185,4264,96/2185,2265,51 0,686 2182,4464,85/2184,5864,71 0,686
PRE-POST Scotopic B-wave 333,8066,45/331,5264,04 0,345 332,0263,52/333,4266,59 0,892 327,1866,16/323,5668,55 0,225
PRE-POST Photopic A-wave 2146,3261,71/2142,0863,82 0,043 2143,8660,98/2139,5062,27 0,043 2137,1066,19/2136,9262,14 0,5
PRE-POST Photopic B-wave 102,3061,12/101,2261,40 0,043 100,6661,53/100,1861,02 0,5 99,0862,34/97,9462,27 0,465
6 7 8
mean ± SD P value mean ± SD P value mean ± SD P value
PRE-POST Scotopic A-wave 2192,6264,35/2185,2265,08 0,08 2188,9865,06/2188,5467,02 0,893 2188,6068,49/2189,3065,08 0,893
PRE-POST Scotopic B-wave 334,0663,27/321,1268,26 0,08 323,3064,94/326,72610,22 0,686 324,92610,65/327,4667,54 0,893
PRE-POST Photopic A-wave 2143,5264,40/2136,8065,09 0,08 138,8864,92/2140,3666,06 0,786 2138,0067,33/2140,5264,99 0,5
PRE-POST Photopic B-wave 101,6461,99/98,6062,65 0,08 99,3262,32/99,4863,68 0,684 98,2263,36/100,5262,42 0,225
doi:10.1371/journal.pone.0096872.t002
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dose. Thereafter we used corrected DHA concentrations in order
to establish the range of optimal doses administered as a single
dose injection.
During the first period of the study, 8 rabbits were used. A
control group of 2 rabbits (Group 1) was injected intravitreally
with 0.05 ml of the vehicle solution (saline solution); other 3
groups of 2 animals each were injected intravitreally with different
concentrations of intravitreal DHA (group 2 received 0.05 ml
containing 2.5 mg of DHA; group 3 received 0.05 ml containing
5 mg of DHA; and group 4 received 0.05 ml containing 10 mg of
DHA).
During the second period of the study, we used 8 rabbits. A
control group of 2 rabbits (Group 5) was injected intravitreally
with 0.05 ml of the vehicle solution (saline solution); other 3
groups of 2 animals each, were injected intravitreally with different
concentration of intravitreal DHA (group 6 received 0.05 ml
containing 5 mg of DHA; group 7 received 0.05 ml containing
25 mg of DHA; and group 8 received 0.05 ml containing 50 mg mg
of DHA).
The rabbbits were anesthetized with a mixture of ketamine
hydrochloride (50 mg/ml) and xylazine hydrochloride (5 mg/ml).
Topical anaesthesia was applied using oxibuprocaine hydrochlo-
ride 1 mg/ml and tetracaine hydrochloride 4 mg/ml (Colircusi
Anestesico Doble, Alcon laboratories, Barcelona, Spain). Diluted
povidone-iodine solution was applied before and after injection.
Intravitreal injections were performed using a 32-gauge needle
attached to a syringe inserted 2 mm posterior to the limbus in the
inferior temporal quadrant. All rabbits were treated with daily
application of fluoroquinolone ointment (ciprofloxacine) after the
injection as antibiotic prophylaxis.
Slit lamp and indirect funduscopic examinations were per-
formed in all eyes immediately after the injections and after 1
week. We evaluated changes in the cornea, lens, vitreous, retina
and optic nerve.
Electroretinogram
The right eyes of all animals were evaluated by electroretinog-
raphy (ERG) at baseline and 1 week after the injection. After
inducing mydriasis with 1 drop of tropicamide (1%), the animals
were dark-adapted for at least 1 hour, and then standard full-field
ERGs were recorded using a corneal contact lens ERG-jet
electrode (MicroComponents, UniversoPastique, Switzerland).
The reference and ground electrodes were stainless surgical
needles (NeuroLine, Ambu Lab, Ballarup, Denmark), that were
placed subcutaneously at the forehead (ground) and ear (refer-
ence). The ERG signals were recorded using the hand-held
portable ERG system EPH-01 (Ephio´s ab, Rejmyre, Sweden). The
dark-adapted scotopic response (rod response) and the scotopic
response (maximal response, cone and rod) were recorded. Flash
intensity was 1.7 cd-s/m-2 and acquisition time was 200 msec for
each registration. The amplitudes of A- and B-waves were
calculated at baseline and 1 week after the injection. ERG
changes were considered significant if the differences in amplitude
(A- and B-waves) from baseline to the final values were higher than
30%. [5]. ERG data were interpreted and interferences were
automatically removed with the software of EPH-01 1.2 version
(Ephio´s ab, Rejmyre, Sweden).
Clinical Examination
Eyes were clinically examined at baseline, immediately before
the injection and one week after the injection. Pupils were dilated
with tropicamide eye drops. The following parameters were
recorded through the slit lamp examination: corneal transparency,
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conjunctival appearance, anterior chamber, iris and lens status,
and ocular fundus characteristics.
All eyes were examined by indirect ophthalmoscopy with a 20 D
lens for imaging of the retina in order to exclude possible diseases
affecting the vitreous, retina and choroid.
Histological Examination
One week after the intravitreal injection the animals were
euthanized with a lethal overdose of endovenous pentobarbital
(100 mg/kg) into the ear vein. Drops of physiological saline were
applied to the eyes to prevent drying. Aqueous humour and
vitreous samples were obtained, deposited in labelled Eppendorf
tubes (500 ml), frozen at 280uC and stored until processing.
Immediately, the eyes were operated under a dissection binocular
microscope. Each eye was fixed with angled forceps to cut away
the conjunctiva by Wescott scissors. The extraocular muscles and
the retrobulbar optic nerve attached to the globe were cut and the
eyeball was lifted from the orbit. The eyeball was rinsed in PBS.
Then the globe was inmovilized and the sclera was incised 2 mm
posterior to the limbus to facilitate fixation with 10% buffered
formalin. After 72 hours, the eyes were sectioned at the retro-
equatorial level to obtain small pieces of the retina that were
oriented and separately dehydrated in a series of 95% ethanol, and
embedded in paraffin. Retinal trans-sections of 5-mm thickness
were collected on poly-L-lysine–coated microscopic slides for H&E
staining and Masson trichrome, and the slides were examined by
light microscope (BX-50; Olympus, Tokyo, Japan) and photo-
graphed with a digital video camera (DP-71 CCD; Olympus). [6]
A morphologic examination of the retina was performed
evaluating the loss of cellular elements, cell disorganization,
apoptotic cells or necrotic degeneration. Morphometric analyses
were performed on the retinal trans-sections to evaluate the total
retinal thickness and layering (ganglionar cell layer, inner
plexiform layer, inner nuclear layer, outer plexiform layer and
outer nuclear layer/photoreceptor layer) and the density of stained
nuclei within the ganglion cell layer, which was determined in the
vicinity of the optic disc, where the density of these cells is more
stable and changes little with direction or eccentricity. [7]
Aqueous and vitreous humor samples analysis
Concentrations of the principal fatty acids in the aqueous and
vitreous humor samples were measured by gas chromatography in
the laboratory of chemistry of the University of Barcelona
(Barcelona, Spain).
Statistical analysis
We analyzed the results of the different studied parameters by
the SPSS 21.0 (IBM Corp). Non-parametric tests (Kendall’s Tau
and Spearman’s Rho) were used to perform the correlation of the
different DHA doses and the electroretinography and histological
parameters. In the comparison of independent variables, we used
the Mann Whitney’s U test and for the dependent variables we
analyzed the data with Wilcoxon test.
Results
Clinical Examination
No complications directly related to the intravitreal injection
were evidenced (cataract, vitreous haemorrhage or retinal
detachment). Color photographs of the eyes are shown in Figure 1.
In the first period of the study, slit lamp examination revealed a
significant ocular inflammation in the rabbits included in group 4
(10 mg/50 ml), with one case of acute corneal melting with ectasia
and mild surrounding edema. This was managed with ciproflox-
acine ointment in order to avoid any misinterpretation of the
inflammation. Through the follow-up the inflammation decreased
and the corneal melting resolved with a final corneal opacity. A
mild-moderate perikeratic conjunctival hyperaemia was also
remarkable in groups 2 and 3 directly proportional to the injected
concentration. Thus, concentrations of DHA used in groups 2, 3
and 4 (2’5 mg/50 ml, 5 mg/50 ml and 10 mg/50 ml respectively)
were considered clinically unsafe.
Slit lamp examination in the second period of the study in
groups 6, 7, 8 was unremarkable, with no signs of inflammation
and no corneal, lens or vitreous opacity. In addition, no clinical
manifestations were observed in control groups (groups 1 and 5).
No signs of retinal necrosis or cystic degeneration were observed in
any of the groups.
Electroretinogram
No statistically significant changes in A- and B- waves
amplitudes measured in scotopic and photopic conditions were
observed comparing ERG data at baseline (before injection) and 1
week after intravitreal injection of the different concentrations of
DHA (Data are summarized in Table 2). In addition, post-
injection ERG study did not show significant differences between
control eyes and DHA-injected eyes (Table 3). There was no
statistically significant correlation between the DHA injected dose
and the post-injection ERG data according the Kendall’s Tau tests
(Scotopic A-wave p= 0,906; Scotopic B-wave p= 0,887; Photopic
A-wave p= 0,256 and Photopic B-wave p= 0,152).
Histological Examination
The retinal morphologic examination with light microscopy did
not evidence any retinal pigment epithelium or neurosensory
retina abnormality in the eyes of rabbits injected with the different
Figure 2. The light microscopy histological examination of each group, labeled on top of each image, did not show any sign of
retinal disarrangement, cellular apoptosis or ischemia.
doi:10.1371/journal.pone.0096872.g002
Anatomical and Functional Safety of DHA
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concentrations of DHA compared with control rabbits (injected
with saline solution). No disarrangement of photoreceptors was
evidenced. There were no signs of cellular apoptosis or ischemia
(Figure 2).
The morphometric parameters analyzed and the statistical
analysis are summarized in the Table 4. The morphometric
analysis did not reveal any statistically significant correlation
between the DHA injected dose and the different retinal thickness
measures according with Kendall’s Tau tests (total retinal
thickness, p = 0.892; ganglionar cell layer, p= 0.136; inner
plexiform layer, p = 0.828; inner nuclear layer p= 0.836; outer
plexiform layer p = 0.942; outer nuclear layer-photoreceptors
p = 0.705). However the Mann-Whitney’s U test evidenced
statistically significant differences between the control groups (1
and 5) and group 8 in the total retinal thickness (p.0.001), the
outer plexiform layer thickness (p = 0.024), and the outer nuclear
layer/photoreceptor thickness (p = 0.018). Further comparisons
between the different retinal measures of DHA injected eyes and
control eyes did not evidenced any other significant differences for
the groups 2, 3, 4, 6 and 7.
The mean density of stained ganglionar cell nuclei did not
showed any statistically significant correlation between the DHA
injected dose (p = 0,784). No statistically significant differences in
the number of ganglionar cell nuclei between control eyes and
DHA-injected eyes were evidenced (Table 5).
Aqueous and vitreous humor samples analysis
Concentrations of the principal fatty acids in the aqueous and
vitreous humor samples of eyes treated with DHA compared with
control eyes are summarized in Table 6. We found statistically
significant differences in the concentration of DHA in vitreous
samples between the control group and all the DHA-injected
groups. In the aqueous humor samples we only found statistically
significant differences between the control group and group 4
(which was injected with the higher dose of DHA: 10 mg/50 ml).
Discussion
The retina is extremely susceptible to oxidative damage. In
contrast, it is well known the essential role of omega-3 PUFAs in
maintaining the retinal function and integrity and there are several
reports of the protective role against oxidative stress. [1–4,8]
Furthermore the loss of DHA-rich photoreceptors cells in the
retina constitutes a hallmark of different retinal degenerations such
as age-related macular degeneration (AMD), retinitis pigmentosa,
Stargardt disease or glaucoma. [9] A number of epidemiological
studies have suggested that lower dietary intakes and lower
circulating concentrations of DHA are associated with higher risk
of AMD, [10] whereas other reports have shown lower levels of
DHA in the plasma and the erythrocytes of patients with retinitis
pigmentosa [11] or primary open angle glaucoma. [12–13] These
data led to the design of several dietary supplementation trials
including DHA for AMD, [14–15] Stargardt disease, [16] Best’s
maculopathy [17] and retinitis pigmentosa [18–19] and to the
commercialization of DHA-rich dietary supplements with the aim
of maintaining or increasing retinal DHA concentrations in the
retina. These studies reported the efficacy of supplementation in
AMD [13–14] and retinitis pigmentosa, [18] and showed a
remarkable influence in some functional parameters, albeit no
benefit was achieved with the short-term treatment for Stargardt’s
disease [16] or Best disease. [17]
Beneficial effects of DHA supplementation are significant in
patients with AMD. Even when AMD does not lead to blindness,
there is a strong negative impact on the independence and the
quality of life. [20] Despite the magnitude of this problem, very
few factors have been identified as capable to modify the natural
course of AMD once signs of early -small-intermediate hard
drusen (# 124 mm) and/or retinal pigment epithelium (RPE)
changes- or intermediate –some large soft drusen (.124 mm) and/
or geographic atrophic patches without central macular involve-
ment- AMD appear.
To the best of the authors’ knowledge, the safety of intravitreal
injection of purified DHA has not previously been reported. We
have used six different concentrations of purified DHA. Due to the
mild-moderate inflammatory reaction induced directly propor-
tional to the concentration of DHA we considered unsafe the
concentrations of 10 mg/50 ml, 5 mg/50 ml, 2.5 mg/50 ml. Thus
we corrected the doses of purified DHA in a second phase of the
study and the results of our study suggest that DHA may be a safe
intravitreal drug in the rabbit model up to 25 mg/50 ml, with no
evidence of toxicity in the slit-lamp examination, ERG data and
light microscopy histologic analysis. The maximal tolerated dose
was 0.05 ml of 25 mg/50 ml DHA. The safe dose range of DHA in
the present study was 5 mg/50 ml to 25 mg/50 ml.
We hypothesize that the intravitreal administration of DHA into
the vitreous may be a potential therapy to prevent the progression
of degenerative retinal diseases by restoring the high concentration
of DHA in the retina and modulating different homeostatic
mechanisms. The limitations of our study to draw final conclusions
about the safety of intravitreal DHA include: the short number of
rabbits used, the differences between the rabbit and the human
retinas and the restrictions in the functional tests subsequent of
working with an animal model.
In conclusion, this preliminary study suggests that intravitreal
DHA is safe up to 25 mg/50 mL in the rabbit eye. Further studies
are warranted to evaluate the safety and efficacy of intravitreal
DHA in human eyes.
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